Quantum Computing Inc. to Unveil Photonics-Based Reservoir Computer, Neurawave, at SuperCompute25
Get Alerts QUBT Hot Sheet
Join SI Premium – FREE
-
New PCIe-based platform marks a major milestone in QCi's photonic quantum roadmap
-
Visit Booth #4344 |
St. Louis, Missouri |November 1 8–20, 2025
Neurawave represents a significant milestone for QCi as it delivers a photonic computing system designed to meet industry standards and seamlessly integrates with existing computing infrastructures. Built in a standard PCIe interface, Neurawave combines cutting-edge optical computing with digital electronics to offer a practical, scalable, and energy-efficient solution for high-performance applications.
Operating fully at room temperature with a compact design, Neurawave brings QCi's technology roadmap into sharp focus by moving from lab-based innovation toward real-world systems that are scalable, relevant, deployable, and ready to advance quantum computing across industries.
Reservoir computing is especially suited for edge-AI use cases such as signal processing, time-series forecasting, and pattern recognition, where rapid response and compact systems are essential. By leveraging the dynamic properties of photonic systems, Neurawave delivers fast, energy-efficient performance ideal for field operations, industrial settings, and embedded applications, and adding hardware-based intelligence and data processing capabilities to QCi's quantum products.
"This launch marks a good step forward for QCi," said Dr.
While Neurawave will be on display at Booth #4344, QCi will also provide on-cloud demonstrations to its Dirac-3 quantum computer, allowing SC25 attendees to explore real-time quantum processing already in use today.
About Quantum Computing Inc.
Quantum Computing Inc. (Nasdaq: QUBT) is an innovative, integrated photonics and quantum optics technology company that provides accessible and affordable quantum machines to the world today. QCi's products are designed to operate at room temperature and low power at an affordable cost. The Company's portfolio of core technologies and products offer unique capabilities in the areas of high-performance computing, artificial intelligence, and cybersecurity, as well as remote sensing applications.
Company Contact:
IMS Investor Relations
Forward-Looking Statements
This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements and forecasts, generally identified by terms such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," "aim to," or variations of these or similar words, involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief, or current expectations of QCi and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including the performance of QCi's photonic products, their compatibility with existing IT infrastructure and their suitability for AI use cases, and that actual results may differ materially from those contemplated by such forward-looking statements. Except as required by federal securities law, QCi undertakes no obligation to update or revise forward-looking statements to reflect changed conditions.
View original content to download multimedia:https://www.prnewswire.com/news-releases/quantum-computing-inc-to-unveil-photonics-based-reservoir-computer-neurawave-at-supercompute25-302616627.html
SOURCE Quantum Computing Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Antier Announces Integrated RWA Tokenization Services Under One Roof
- Global Times: Through blood donation, medical practice, and policy consultation, I experience CPC-led social welfare development in Shanghai for years: Nepali Magnolia Gold Award recipient
- Innovative Molecules Announces First Patient Dosed in Phase 2a Trial of Adibelivir (IM-250), Advancing Company into Late-Stage Clinical Development
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share